Targeting VEGF receptors in kidney cancer.

[1]  R. Motzer,et al.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. , 2007, The Lancet. Oncology.

[2]  M. Atkins,et al.  Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer , 2007, Clinical Cancer Research.

[3]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[4]  W Marston Linehan,et al.  The genetic basis of cancer of the kidney. , 2003, The Journal of urology.

[5]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[7]  W Marston Linehan,et al.  Focus on kidney cancer. , 2004, Cancer cell.

[8]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[9]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[10]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[11]  E. Mazeman.  [CANCER OF THE KIDNEY]. , 1963, Lille chirurgical.